- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01642901
Zoledronic Acid in Acute Spinal Cord Injury
Zoledronic Acid to Prevent Bone Loss After Acute Spinal Cord Injury
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University and Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ages 18-65, male or female
- Traumatic SCI with Neurological level C4-T10, American Spinal Injury Association (ASIA) Impairment Scale (AIS) A,
- Serum calcium level >7.0 mg/dL) at time of study drug administration
- Screening baseline serum 25-hydroxy (25-OH) vitamin D of at least 13 ng/ml
- No medical contraindication to supplemental vitamin D for participants whose levels are >13 ng/ml but sub-therapeutic (<32ng/ml)
- No medical contraindication to supplemental calcium
- Weight under 300 pounds, which is the maximum permitted on the dual-energy X-ray absorptiometry (DXA) scanner
Exclusion Criteria:
- Ventilator-dependent individuals
- Chronic steroid use (defined as >6 months)
- Rheumatoid disease with use of prior disease modifying anti-rheumatic drugs (DMARDs) affecting bone density
- History of osteoporosis or of treatment for osteopenia or osteoporosis with bisphosphonates, or selective reuptake estrogen modifying agents
- Current use of medications* including bisphosphonates to treat osteoporosis (*note that prior calcium or vitamin D use is not an exclusion criteria)
- History of more than one lower extremity osteoporosis-related fracture
- Chronic renal insufficiency, creatinine clearance < 35 ml/min, during screening
- End stage liver or kidney disease
- Medical conditions resulting in hypogonadal states that affect bone density
- Uncontrolled thyroid disease/thyrotoxicosis
- Hereditary or acquired metabolic bone disorder
- History of use of unfractionated heparin for >1 year
- History of selected antiseizure medications, specifically phenobarbital, phenytoin, carbamazepine, sodium valproate >1 year
- Acute or chronic bilateral lower extremity fractures involving tibia or femur, with placement of surgical hardware in any areas of above locations
- Severe hypotension requiring use of intravenous blood pressure agents such as dopamine, norepinephrine or phenylephrine. Exception may allow for patients on pressors who arm experiencing hypotension as they acclimate to upright posture.
- Inability to provide informed consent and understand the consent process
- Facial fractures requiring oral surgery
- Dental surgery or oral maxillofacial surgery within 2 weeks of anticipated study drug administration
- Pregnancy present on admission
- Vitamin D deficiency on admission testing (serum 25-OH D reported as < 13 ng/mL)
- Patients with an established reaction to, or history of, anaphylactic shock to aspirin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zoledronic Acid 5 mg IV infusion
Single infusion of 5 mg intravenous zoledronic acid given within 21 days of acute traumatic spinal cord injury.
|
5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
Other Names:
|
Placebo Comparator: normal saline 0.9%
Infusion of normal saline of equivalent volume to reconstituted zoledronic acid, given only once and run over 2 hours, to occur within 21 days of acute traumatic spinal cord injury.
|
Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Areal Bone Mineral Density at Hip
Time Frame: 4 months
|
Percent change in areal bone mineral density (aBMD) assessed by dual energy X-ray absorptiometry (DXA) at 4 months compared to baseline. This will compare aBMD at the hip. |
4 months
|
Change in Areal Bone Mineral Density at Knee
Time Frame: 4 months
|
Percent change in areal bone mineral density (aBMD) assessed by dual energy X-ray absorptiometry (DXA) at 4 months compared to baseline. This will compare aBMD at the distal femur and proximal tibia. |
4 months
|
Change in Areal Bone Mineral Density at Hip
Time Frame: one year
|
Percent change in areal bone mineral density (aBMD) assessed by dual energy X-ray absorptiometry (DXA) at 12 months post-injury compared to baseline. This will compare aBMD at the hip. |
one year
|
Change in Areal Bone Mineral Density at Knee
Time Frame: one year
|
Percent change in areal bone mineral density (aBMD) assessed by dual energy X-ray absorptiometry (DXA) at 12 months post-injury compared to baseline. This will compare aBMD at the distal femur and proximal tibia. |
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Biomarkers of Bone Resorption (sCTX)
Time Frame: 1 month, 4 months, 12 months
|
Change in sCTX from baseline to 1- and 4-months post intervention and 12-months post-injury.
|
1 month, 4 months, 12 months
|
Change in Biomarkers of Bone Formation (P1NP)
Time Frame: 1 month, 4 months
|
Change in serum P1NP from baseline to 1- and 4-months post intervention.
|
1 month, 4 months
|
Safety and Tolerability of Zoledronic Acid
Time Frame: 72-hours and 1 month post intervention.
|
Assessment of the safety and tolerability of zoledronic acid in the acute spinal cord injury population.
This will be done by examination reportable adverse events including fevers, flu-like symptoms, GI upset as measures of safety and report of patient's willingness to have participate in physical therapy in the first week after receiving medication as a measure of tolerability
|
72-hours and 1 month post intervention.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christina V Oleson, MD, Thomas Jefferson University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11F.612
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injury
-
Taipei Veterans General Hospital, TaiwanThe Industrial Technology Research InstituteUnknownSpinal Cord Injuries | Complete Spinal Cord Injury | Incomplete Spinal Cord InjuryTaiwan
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingSCI - Spinal Cord Injury | Incomplete Spinal Cord InjuryUnited States
-
Jill M. Wecht, Ed.D.Icahn School of Medicine at Mount SinaiRecruitingBlood Pressure | Spinal Cord Injuries | SCI - Spinal Cord Injury | Blood Pressure Disorders | Traumatic Spinal Cord Injury | Acute Spinal Cord Injury | Neuromodulation | Spinal Cord StimulationUnited States
-
MetroHealth Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS); Case Western...RecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury CervicalUnited States
-
NervGen PharmaRecruitingSpinal Cord Injuries | Chronic Spinal Cord Injury | Subacute Spinal Cord InjuryUnited States
-
Kevin KilgoreNational Institute of Neurological Disorders and Stroke (NINDS); Case Western... and other collaboratorsRecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury Cervical | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C5-C7 Level With Incomplete LesionUnited States
-
The University of Texas Health Science Center,...TerminatedSpinal Cord Injuries | Cervical Spinal Cord Injury | Traumatic Spinal Cord CompressionUnited States
-
S.Biomedics Co., Ltd.Yonsei University; Linical Co., Ltd.RecruitingSpinal Cord Injury, Acute | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C4 Level With Complete LesionKorea, Republic of
-
Mahidol UniversityRecruitingSpinal Cord Injury | Incomplete Spinal Cord InjuryThailand
-
Kessler FoundationNew Jersey Commission on Spinal Cord ResearchRecruitingSpinal Cord Injuries | Incomplete Spinal Cord InjuryUnited States
Clinical Trials on Zoledronic acid
-
University of CalgaryRecruitingOsteo Arthritis Knee | Anterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearCanada
-
Yonsei UniversityRecruiting
-
Novartis PharmaceuticalsCompleted
-
Thomas J. SchnitzerNovartisTerminatedBone LossUnited States
-
University of CalgaryRecruitingOsteoporosis | Bone Loss | Osteopenia | Osteoporosis, PostmenopausalCanada
-
Columbia UniversityNovartis PharmaceuticalsCompletedLiver Transplantation | Heart Transplantation | Bone ResorptionUnited States
-
Toufiqe-E-EalahiRecruiting
-
Children's Hospital of Eastern OntarioWithdrawnAcute Lymphoblastic Leukemia | Osteoporosis | OsteonecrosisCanada
-
Stanford UniversityNational Institutes of Health (NIH)WithdrawnBone Marrow Transplant | Hematopoietic Stem Cell Transplant
-
Novartis PharmaceuticalsCompleted